OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026
Summary
OrsoBio shared positive Phase 2a data for TLC-2716, an LXR inverse agonist, in patients with severe hypertriglyceridemia and MASLD. The announcement centers on clinical efficacy and safety signals presented at ENDO 2026. The content points to continued development in the biotech and pharma research pipeline. It does not describe a product launch, financing event, acquisition, or personnel change.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected